Insider-Led Growth Stocks To Watch In December 2024

In This Article:

As global markets navigate the complexities of interest rate adjustments and political uncertainties, investors are closely watching how these factors impact major indices. Despite recent declines in U.S. stocks and broader market volatility driven by cautious Fed commentary, opportunities for growth remain, particularly in companies with strong insider ownership that can leverage their leadership's vested interests to drive long-term success. In such an environment, stocks led by insiders who have a significant stake may offer a compelling proposition due to their alignment with shareholder interests and potential resilience amidst fluctuating economic conditions.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

Arctech Solar Holding (SHSE:688408)

37.9%

25.6%

Seojin SystemLtd (KOSDAQ:A178320)

30.9%

39.9%

People & Technology (KOSDAQ:A137400)

16.4%

37.3%

Archean Chemical Industries (NSEI:ACI)

22.9%

41.3%

SKS Technologies Group (ASX:SKS)

29.7%

24.8%

Kirloskar Pneumatic (BSE:505283)

30.3%

26.3%

Laopu Gold (SEHK:6181)

36.4%

34.2%

Plenti Group (ASX:PLT)

12.8%

120.1%

Brightstar Resources (ASX:BTR)

16.2%

84.5%

Findi (ASX:FND)

34.8%

112.9%

Click here to see the full list of 1512 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Pharma Mar

Simply Wall St Growth Rating: ★★★★★★

Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across various international markets with a market cap of €1.40 billion.

Operations: The company's revenue primarily comes from its oncology segment, generating €154.75 million.

Insider Ownership: 11.8%

Pharma Mar demonstrates potential as a growth company with high insider ownership, despite recent volatility. Its earnings are forecast to grow significantly at 56.19% annually, outpacing the Spanish market. The company's revenue is also expected to rise by 25.4% per year. Recent positive trial results for Zepzelca® could bolster future growth prospects, although profit margins have declined from 8.3% to 0.4%. Trading at a substantial discount to its estimated fair value enhances its appeal for investors seeking undervalued opportunities with growth potential.

BME:PHM Ownership Breakdown as at Dec 2024
BME:PHM Ownership Breakdown as at Dec 2024

Beijing Fourth Paradigm Technology

Simply Wall St Growth Rating: ★★★★☆☆